Comparing the thromboembolic risk with KRd versus VRd in newly diagnosed myeloma

Shaji Kumar: Comparing KRd With VRd in Newly Diagnosed MyelomaПодробнее

KRd vs VRd as Induction Therapy in Newly Diagnosed High-Risk Multiple MyelomaПодробнее

KRd versus VRd in patients with newly diagnosed multiple myelomaПодробнее

KRD vs VRD in high-risk multiple myeloma prior to autoHSCTПодробнее

KRd vs VRd for initial therapy of newly diagnosed multiple myelomaПодробнее

What are the results from the ENDURANCE trial that compares KRd to VRd in newly diagnosed patients?Подробнее

Debate: anti-CD38-VRd quads versus anti-CD38-KRd quads in newly diagnosed myelomaПодробнее

GRIFFIN Trial Update - DVRd vs VRd in Newly Diagnosed Myeloma | Peter Voorhees, MD | ASH 2021Подробнее

Treatment intensity in frail patients with newly diagnosed multiple myeloma: VRd vs RdПодробнее

IMROZ: Isa-VRd vs VRd for transplant-ineligible newly diagnosed multiple myelomaПодробнее

ENDURANCE trial: KRd versus VRd for initial therapy of NDMMПодробнее

Elotuzumab plus KRd versus KRd for newly diagnosed multiple myeloma: Phase III trial resultsПодробнее

ENDURANCE: RVD vs KrD for myelomaПодробнее

Results of ENDURANCE (E1A11) phase III trial: KRd versus VRd for initial therapy of NDMMПодробнее

Real-world comparison of RVD vs D-RVD in newly diagnosed transplant-eligible multiple myelomaПодробнее

KRd vs KTd followed by K maintenance or control for high-risk myelomaПодробнее

DEBATE: Which initial therapy for younger fit patients is best? - KRD and VRDПодробнее

Isa-VRd vs VRd for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (IMROZ)Подробнее

Quadruplets in Newly Diagnosed Transplant-Ineligible MyelomaПодробнее